August 12 -- Lepu Medical Technology (300003.SZ) filed its net profit and revenue respectively grew 26 percent and 23 percent year-on-year to 260 million yuan and 470 million yuan in the first half for EPS of 0.3243 yuan, reports yicai.com. Sales of stents, the company’s major product, contributed revenue of 350 million yuan but with gross margin downs to 88.57 percent in the first half.

Lepu obtained CE certification on four products in the first half and has certified 15 products so far. It has established agent sales systems in 40 countries and recorded sales income growth of 321 percent year-on-year.

Source:capitalvue